November 4, 2021 12:25 PM EDT
Manufacturing

Hic­cup in man­u­fac­tur­ing will cause Gen­Sight to re­peat the process for reti­nal gene ther­a­py; Den­dreon an­nounces col­lab­o­ra­tion with Shore­line Bio­sciences

Josh Sullivan

Four months af­ter a gene ther­a­py Phase III tri­al for reti­nal neu­rode­gen­er­a­tive dis­eases from French biotech Gen­Sight failed de­spite im­prove­ment in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times